Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6812401 | 0.87 | STS (0.53) | SMN1; SMN2NPC1MAPTHPGDL3MBTL1 | |
| SCHEMBL2099644 | 0.85 | GSK3B (0.59) | NPC1 | |
| SCHEMBL6808336 | 0.82 | NPC1 (0.41) | RAB9ANPC1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL5888776 | 0.82 | GSK3B (0.40) | NPC1MAPTL3MBTL1KMT2AMEN1 | |
| SCHEMBL2099655 | 0.80 | MAPT (0.55) | SMN1; SMN2RAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL2163425 | 0.80 | KMT2A (0.58) | SMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL3096964 | 0.80 | CA12 (0.54) | RAB9ANPC1ALDH1A1MAPTTDP1 | |
| SCHEMBL2103554 | 0.80 | STS (0.54) | RAB9ANPC1MAPTL3MBTL1KMT2A | |
| SCHEMBL8709906 | 0.80 | GSK3B (0.38) | RAB9ANPC1ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL6307030 | 0.79 | KMT2A (0.39) | SMN1; SMN2RAB9AALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163770-B2 | Benzoxathiin derivative | MSD. K. K. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20100168156-A1 | Novel Benzoxathiine Derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-1944301-A1 | NOVEL BENZOXATHIIN DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-5710168-A | 2-piperidino-1-alkanol derivatives as neuroprotective agents | PFIZER INC. (US) | 1998-01-20 | — | — | US | disclosed |
| US-5527912-A | USEFUL INTREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. (US) | 1996-06-18 | — | — | US | disclosed |
| US-5391742-A | Intermediates for 2-piperidino-1-alkanols | PFIZER INC. (US) | 1995-02-21 | — | — | US | disclosed |
| US-5338754-A | 2-pyrrolidino-1-alkanol derivatives as antiischemic agents | PFIZER INC (US) | 1994-08-16 | — | — | US | disclosed |
| US-5272160-A | 2-piperidino-1-alkanol derivatives as antiischemic agents | PFIZER INC (US) | 1993-12-21 | — | — | US | disclosed |
| US-5185343-A | NORTROPYL-1-ALKANOL DERIVATIVES AS ANTIISCHEMIC AGENTS | PFIZER INC. (US) | 1993-02-09 | — | — | US | disclosed |
| WO-1990014087-A1 | 2-PIPERIDINO-1-ALKANOL DERIVATIVES AS ANTIISCHEMIC AGENTS | PFIZER INC. (US) | 1990-11-29 | — | — | WO | disclosed |
| WO-1990014088-A1 | 2-PIPERIDINO-1-ALKANOL DERIVATIVES AS ANTIISCHEMIC AGENTS | PFIZER INC. (US) | 1990-11-29 | — | — | WO | disclosed |
| CN-1047291-A | The 2-of anti-ischaemic agent croak pyridine subbase-1-alkanol derivatives | PFIZER (US) | 1990-11-28 | — | — | CN | disclosed |
| EP-0398578-A2 | 2-piperidino-1-alkanol derivatives as antiischemic agents | PFIZER INC. (US) | 1990-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168156-A1 | Novel Benzoxathiine Derivative | XDH, GPR119, BRIX1 | ABCB1 1907/4885SMN1; SMN2 3660/4885RAB9A 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.